Latest stories on BBIO
H.C. Wainwright reiterates BridgeBio Pharma stock rating on FDA filing
Investing.com Analyst Ratings56 · neutralanalyst
BridgeBio’s Encaleret NDA Accepted by U.S. FDA
TipRanks67 · bullishproduct/pr
BridgeBio Pharma, Inc. (BBIO) files 8-K
SEC 8-K50 · neutralgeneral
BridgeBio granted FDA review for hypoparathyroidism therapy
Seeking Alpha67 · bullishproduct/pr
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 | BBIO Stock News
StockTitan73 · bullishproduct/pr
Yext, Mission Produce, and 3 More Stocks See Activist Action
Barron's50 · neutralgeneral
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
MarketBeat34 · bearishproduct/pr
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
Seeking Alpha73 · bullishanalyst
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News
StockTitan50 · neutralgeneral
BridgeBio stock jumps after rival heart drug fails key trial
The Street67 · bullishproduct/pr
U.S. Markets Closed Up Thursday; BridgeBio Pharma Led Increases
Barron's63 · neutralgeneral
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
Stocktwits News34 · bearishgeneral
S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead
Barron's73 · bullishgeneral
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis
Seeking Alpha67 · bullishproduct/pr
BridgeBio Raises $934 Million via Preferred Equity Financing
TipRanks28 · bearishgeneral
BridgeBio Pharma, Inc. (BBIO) files 8-K
SEC 8-K50 · neutralgeneral
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM | BBIO Stock News
StockTitan67 · bullishproduct/pr
BridgeBio secures up to $1B in preferred equity
Seeking Alpha24 · bearishgeneral
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches | BBIO Stock News
StockTitan24 · bearishgeneral
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street
Seeking Alpha63 · neutralgeneral
Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity
Bloomberg55 · neutralgeneral
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish
Seeking Alpha67 · bullishproduct/pr
BridgeBio Pharma, Inc. (BBIO) files 8-K
SEC 8-K50 · neutralgeneral
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News
StockTitan50 · neutralgeneral